What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?
https://doi.org/10.37489/2588-0519-2020-S4-47-49
Abstract
Some guidelines describe combined use of hydroxychloroquine and lopinavir/ritonavir as one of the treatment alternatives for severe COVID-19, yet this treatment is not preferable. It requires careful consideration of possible interactions with other drugs, monitoring of cardiotoxicity (including QT-interval measurement), and hepatotoxicity (measurement of ASAT/ ALAT).
About the Authors
Yu. Yu. Kiselev
Oslo Metropolitan University
Norway
Norway
Kiselev Yuri Yu. – PhD, Associate Professor at the Faculty of Health Sciences OsloMet
Oslo
V. M. Tsvetov
Federal Center for Cardiovascular Surgery of the Ministry of Health of Russia
Russian Federation
Russian Federation
Tsvetov Vitaly M. – Candidate of Medical Sciences, Doctor — Clinical Pharmacologist. SPIN code: 3202-7659
Chelyabinsk
K. B. Mirzaev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Mirzaev Karin B. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8308-7599
Moscow
D. A. Sychev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556
Moscow
References
1. State register of medicinal products P N015606/01 (In Russ). Доступно по: https://clck.ru/REWNS Ссылка активна на 20.05.2020
2. Recommended approaches to monitoring the QT interval when taking hydroxychloroquine in COVID-19. (In Russ). Доступно по: https://clck.ru/REWQ8 Ссылка активна на 20.05.2020
3. State register of medicinal products LP-000116. (In Russ). Доступно по: https://clck.ru/REWRX Ссылка активна на 20.05.2020
4. https://covid19evidence.net.au/#living-guidelines
5. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. [cited 2020 May 20]; Available from: https://www.covid19treatmentguidelines.nih.gov/
6. Cao B, Wang Y, Wen D et al. A trial of lopinavir—ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020 May 7;382(19):17871799. DOI: 10.1056/NEJMoa2001282.
7. https://www.england.nhs.uk/coronavirus/secondary-care/other-resources/specialty-guides/#coronavirus-treatment
8. https://www.covid19-druginteractions.org/
9. Temporary guidelines of the Ministry of health of the Russian Federation. (In Russ). Доступно по: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/122/original/28042020_%D0%9CR_COVID-19_v6.pdf Ссылка активна на 20.05.2020
10. Chong VH, Chong PL, Metussin D et al. Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19. J Med Virol. 2020 May 13;10.1002/jmv.26004. DOI: 10.1002/jmv.26004
11. The possibility of using hydroxychloroquine to prevent SARSCoV-2 infection in contact persons and medical professionals. (In Russ). Доступно по: https://clck.ru/REWSr Ссылка активна на 20.05.2020
12. https://clck.ru/REWU8
13. https://reference.medscape.com/drug-interactionchecker
14. National Institute for the Infectious Diseases “L. Spallanzani” IRCCS. Recommendations for COVID-19 Clinical Management. Infect Dis Rep. 2020 Mar 16;12(1):8543. DOI: 10.4081/idr.2020.8543
Review
For citations:
Kiselev Yu.Yu., Tsvetov V.M., Mirzaev K.B., Sychev D.A. What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed? Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(4S):47-49. (In Russ.) https://doi.org/10.37489/2588-0519-2020-S4-47-49
Views:
766
Email this article 